We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Morphosys Receives Novartis Milestone Payment for Phase 1 Trial
News

Morphosys Receives Novartis Milestone Payment for Phase 1 Trial

Morphosys Receives Novartis Milestone Payment for Phase 1 Trial
News

Morphosys Receives Novartis Milestone Payment for Phase 1 Trial

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Morphosys Receives Novartis Milestone Payment for Phase 1 Trial"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

MorphoSys AG has announced that it has received a milestone payment from Novartis in connection with the initiation of a clinical phase 1 trial with a novel HuCAL antibody. The antibody will be tested in the field of prevention of thrombosis.

This is the twelfth therapeutic antibody based on MorphoSys's technologies that Novartis is evaluating in clinical trials. Financial details were not disclosed.

"We are very pleased that another program from our collaboration with Novartis has entered the clinical development stage," commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG.

"During 2016, the MorphoSys pipeline has matured significantly and currently includes more programs in clinical trials than ever before. This again reflects the tremendous value of MorphoSys's technologies and the resulting products, both in our partnered and proprietary pipeline."

MorphoSys's collaboration with Novartis has resulted in twelve clinical programs to date. In total, MorphoSys's proprietary and partnered clinical pipeline currently comprises 27 unique antibody molecules, which are being evaluated in more than 60 active clinical trials.

Advertisement